Elkin, Rena
Oh, Jung Hun
Dela Cruz, Filemon
Norton, Larry
Deasy, Joseph O.
Kung, Andrew L.
Tannenbaum, Allen R.
Funding for this research was provided by:
National Institutes of Health
Air Force Office of Scientific Research
Army Research Office
Article History
Received: 12 October 2022
Accepted: 13 December 2023
First Online: 4 January 2024
Competing interests
: J.O.D. is a shareholder in PaigeAI. This is outside the scope of the submitted work. A.L.K. is on the Scientific Advisory Board of Emendo Biotherapeutics, Karyopharm Therapeutics, Imago BioSciences, and DarwinHealth; is co-Founder and on the Board Directors of Isabl Technologies; and has equity interest in Imago BioSciences, Emendo Biotherapeutics, and Isabl Technologies. These are all outside the scope of the submitted work. None of the other authors report a potential competing interest.